REG - Novacyt S.A. - Notice of rescheduled AGM

Novacyt SAAnnouncement

26/06/2024 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240626:nRSZ0112Ua&default-theme=true

RNS Number : 0112U  Novacyt S.A.  26 June 2024

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Notice of rescheduled AGM

 

AGM to be held online on Thursday 18 July

 

Paris, France, and Eastleigh and Manchester, UK - 26 June 2024 - Novacyt S.A.
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics
company with a broad portfolio of integrated technologies and services,
announces that the Company's Annual General Meeting (AGM), due to take place
earlier today, will be rescheduled and held exclusively as an open online
meeting on Thursday 18 July at 1pm BST/2pm CEST.

 

To function as a procedural meeting, the AGM requires a sufficient number of
shareholder votes to constitute a quorum to ensure the AGM is validly held in
accordance with French corporate law. This threshold has not been met,
therefore, in accordance with Article 19 of Novacyt articles of association,
the AGM has been rescheduled.

 

The agenda will remain the same as in the first convening and the AGM will
comprise of both ordinary and extraordinary resolutions.

 

Shareholders can register to view the AGM via the online meeting platform by
visiting
https://reg.lumiengage.com/novacyt-sa-agm-2024/novacytagm2024/Site/Register
(https://reg.lumiengage.com/novacyt-sa-agm-2024/novacytagm2024/Site/Register)
. Registrations must be accompanied by formal evidence of shareholding.

 

Forms of Proxy already completed and submitted and votes cast by electronic
means for the first AGM remain valid for all meetings subsequently convened
with the same agenda (art. R. 225-77 of the French commercial code). Full
details of dates concerning voting will follow in due course.

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                             +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Stephanie Cuthbert / Paul McManus /                                     +44 (0)7796 794 663 / +44 (0)7980 541 893

 Phillip Marriage / Alice Woodings                                        +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·  Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·     MyGo: real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·  Pharmaceutical research services: whole genome sequencing (WGS) / whole
                      exome sequencing (WES)

 

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the
UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and
Canada and has a commercial presence in over 65 countries. The Company is
listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris
Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGZGZVFVNGDZM